Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ESRRG | P62508 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573628 | 0.88 | NR1H2 (0.45) | NR1H2NR1H3CYP2C19CNR2 | |
| SCHEMBL6763725 | 0.85 | CYP2C19 (0.40) | NR1H2NR1H3CYP2C19NR3C1POLB | |
| SCHEMBL6575322 | 0.83 | CYP2C19 (0.40) | NR1H2NR1H3CYP2C19CNR2ESRRG | |
| SCHEMBL6575826 | 0.77 | ESRRG (0.45) | CNR2ESRRG | |
| SCHEMBL6563349 | 0.75 | CYP2C19 (0.51) | CYP2C19NR3C1NR3C2 | |
| SCHEMBL5186092 | 0.75 | GRIA4 (0.42) | CYP2C19POLB | |
| SCHEMBL6573861 | 0.73 | CYP2C19 (0.47) | CYP2C19NR3C2 | |
| SCHEMBL6573622 | 0.73 | CYP2C19 (0.42) | NR1H2NR1H3CYP2C19NR3C1CNR2 | |
| SCHEMBL5187439 | 0.73 | AR (0.51) | CYP2C19AR | |
| SCHEMBL6762192 | 0.72 | GRIA4 (0.40) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | NR1H2 1419/4885NR1H3 1557/4885CYP2C19 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.